1. ¹Department of Medical Pharmacology and Toxicology, University of California, Davis, California, USA
2. ²Comparative Pathology Laboratory University of California, Davis, California, USA

Correspondence: Dr Heike Wulff, Department of Medical Pharmacology, Genome and Biomedical Sciences Facility, Room 3502, 451 East Health Sciences Drive, University of California, Davis, California 95616. E-mail: hwulff@ucdavis.edu

Received 22 August 2006; Revised 21 October 2006; Accepted 19 November 2006; Published online 1 February 2007.

Abstract

The voltage-gated potassium channel Kv1.3 has been recently identified as a molecular target that allows for selective pharmacological suppression of effector memory T (T_EM) cells without affecting the function of naïve and central memory T cells. We here investigated whether PAP-1, a small molecule Kv1.3 blocker (EC₅₀=2 nM), could suppress allergic contact dermatitis (ACD). In a rat model of ACD, we first confirmed that the infiltrating cells in the elicitation phase are indeed CD8⁺ CD45RC^- memory T cells with high Kv1.3 expression. In accordance with its selective effect on T_EM cells, PAP-1 did not impair sensitization, but potently suppressed oxazolone-induced inflammation by inhibiting the infiltration of CD8⁺ T cells and reducing the production of the inflammatory cytokines IFN-, IL-2, and IL-17 when administered intraperitoneally or orally during the elicitation phase. PAP-1 was equally effective when applied topically, demonstrating that it effectively penetrates skin. We further show that PAP-1 is not a sensitizer or an irritant and exhibits no toxicity in a 28-day toxicity study. Based on these results we propose that PAP-1 could potentially be developed into a drug for the topical treatment of inflammatory skin diseases such as psoriasis.